Strensiq®

Active substance

Asfotase alfa

Holder

Alexion Pharma

Status

Running

Indication

long-term enzyme replacement therapy in patients with - hypophosphatasia (HPP) in whom the first symptoms presented before the age of 18, to treat the bone manifestations of the disease

Public documents

Approbation

Information for the patient

Informed consent

Last update

28/11/2017
Last updated on 28/11/2017